Advanced Enzyme Technologies Launches Open Market Buyback of Shares with Maximum Size Set at ₹697 Million

Advanced Enzyme Technologies Launches Open Market Buyback of Shares with Maximum Size Set at ₹697 Million​

Advanced Enzyme Technologies Limited has announced a public offer for the buyback of its equity shares from the open market, following approval by its Board of Directors. The company is set to utilize the buyback initiative to enhance shareholder value and efficiently deploy surplus cash, underscoring its commitment to optimizing returns for continuing investors.

The buyback process involves purchasing equity shares through the Stock Exchanges (BSE and NSE). The offering has been determined with a Maximum Buyback Size of ₹697,000,000 (Rupees Six Hundred and Ninety Seven Million only), with no single-share price exceeding ₹500/- (Rupees Five Hundred only).

Buyback Timeline and Mandates
The offer for the equity shares is scheduled to open on or before August 14, 2026. The buyback period will conclude earlier of sixty six working days from the opening date, when the Maximum Buyback Size is deployed, or at an earlier period determined by the Board, subject to specific conditions.

The company has set clear utilization mandates:

• Minimum Buyback Size: At least 75% of the maximum size must be utilized towards the buyback, corresponding to ₹522,750,000 (Rupees Five Hundred Twenty Two Million and Seven Hundred Fifty Thousand only). Based on this minimum size, the company would purchase a minimum of 1,045,500 Equity Shares.
• Initial Deployment Target: A minimum of 40% of the Maximum Buyback Size, equivalent to ₹278,800,000 (Rupees Two Hundred Seventy Eight Million and Eight Hundred Thousand only), must be utilized within the initial half of the sixty six working days from the offer opening date.

The indicative maximum number of shares that could be bought back at the Maximum Buyback Price is 1,394,000 Equity Shares, representing approximately 1.25% of the total paid-up equity share capital as of March 31, 2026. The company confirmed that this figure is less than 25% of the total paid-up equity share capital.

Financial Commitment and Rationale
The buyback will be funded from the company’s internal accruals, including free reserves or Securities Premium account. This decision aligns with the company's strategic goal to allocate surplus cash efficiently and enhance long-term shareholder value by reducing its equity capital base.

As of March 31, 2026, the financial status supporting this move shows a Net Worth of ₹7,096.23 million in standalone statements. Furthermore, the company confirmed that the ratio of aggregate secured and unsecured debts owed after the buyback will not be more than twice the paid-up capital and free reserves.

Key Details of the Offer:

The company's management stated that the buyback is expected to improve earnings per share and enhance return on equity by reducing the existing equity shares.

Advanced Enzyme Technologies Limited, a research-driven biotechnology company known for its expertise in enzyme innovation, has committed to transparent market practices throughout this process. The company also confirmed that it holds no defaults regarding interest payments or dividend payment due to any shareholder.

ADVENZYMES Stock Price Movement​

Advanced Enzyme Technologies Limited shares gained in the market today, settling at ₹298.30 after rising by 1.19%. The stock saw a total traded volume of 366,896 shares during the session.